Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0044)
Name
Lidocaine
Synonyms
lidocaine; 137-58-6; Lignocaine; Xylocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Lidoderm; Alphacaine; Duncaine; Esracaine; Xylestesin; Cappicaine; Gravocain; Leostesin; Maricaine; Isicaina; Solcain; Xylocain; L-Caine; Isicaine; Xylocitin; Rucaina; Xilina; Xycaine; Cito optadren; Anestacon; Lida-Mantle; Dentipatch; Xylotox; 2-(Diethylamino)-2',6'-acetoxylidide; Lidocainum; Lignocainum; Cuivasil; Jetocaine; Octocaine; Remicaine; Xilocaina; Xyloneural (free base); Dalcaine; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Lidocaina; ELA-Max; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-; ZTlido; Diethylaminoaceto-2,6-xylidide; 2',6'-Acetoxylidide, 2-(diethylamino)-; alpha-Diethylamino-2,6-dimethylacetanilide; Dilocaine; Versatis; Ztilido; CHEBI:6456; alfa-Dietilamino-2,6-dimetilacetanilide; HSDB 3350; EINECS 205-302-8; NSC 40030; NSC-40030; Lidocaton; Xylocard; Zingo; BRN 2215784; ALGRX 3268; ALGRX-3268; DTXSID1045166; Xylocaine Viscous; UNII-98PI200987; Xylocaine (TN); CHEMBL79; LIDOPEN; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; Diethylaminoacet-2,6-xylidide; MLS000069724; EMLA COMPONENT LIDOCAINE; 98PI200987; DTXCID9025166; ORAQIX COMPONENT LIDOCAINE; SYNERA COMPONENT LIDOCAINE; Xllina; FORTACIN COMPONENT LIDOCAINE; LIDOCAINE COMPONENT OF EMLA; 4-12-00-02538 (Beilstein Handbook Reference); NSC40030; LIDOCAINE COMPONENT OF ORAQIX; LIDOCAINE COMPONENT OF SYNERA; 2-diethylamino-2',6'-acetoxylidide; LANABIOTIC COMPONENT LIDOCAINE; LIDOCAIN COMPONENT OF FORTACINE; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine (VAN); ROCEPHIN KIT COMPONENT LIDOCAINE; .alpha.-Diethylaminoaceto-2,6-xylidide; LIDOCAINE COMPONENT OF LANABIOTIC; NCGC00015611-10; Xilocaina [Italian]; Lanabiotic; SMR000058189; .alpha.-(Diethylamino)-2,6-acetoxylidide; LIDOCAINE COMPONENT OF ROCEPHIN KIT; DIETHYLAMINO-2,6-DIMETHYLACETANILIDE; Rocephin Kit; .alpha.-Diethylamino-2,6-dimethylacetanilide; .omega.-Diethylamino-2,6-dimethylacetanilide; LIDOCAINE (MART.); LIDOCAINE [MART.]; Lidocainum [INN-Latin]; Lidocaina [INN-Spanish]; N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamide; 2-(Diethylamino)-N-(2,6-Dimethylphenyl)ethanamide; EMBOLEX; LIDOCAINE (EP MONOGRAPH); LIDOCAINE [EP MONOGRAPH]; LIDOCAINE (USP MONOGRAPH); LIDOCAINE [USP MONOGRAPH]; DermaFlex; Anestacon Jelly; Xylocaine-Mpf; Zilactin-L; 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide; After Burn Gel; Lidoject-1; Lidoject-2; After Burn Spray; Dentipatch (TN); Octocaine-50; 91484-71-8; CAS-137-58-6; LQZ; Octocaine-100; Xylocaine Test Dose; Xylocaine Endotracheal; Norwood Sunburn Spray; Xylocaine 5% Spinal; 2-2EtN-2MePhAcN; Xylocaine Dental Ointment; MFCD00026733; Xylocaine-Mpf with Glucose; alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Lidocain; Qualigens; Xyline; Lignocaine base; After Burn Double Strength Gel; LidocaineHClH2O; After Burn Double Strength Spray; Lidocaine [USP:INN:BAN:JAN]; Lidocaine, powder; N1-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide; Zingo (Salt/Mix); CDS1_000283; Lidocaine (Alphacaine); Spectrum_001118; Lidothesin (Salt/Mix); Xyloneural (Salt/Mix); LIDOCAINE [INN]; LIDOCAINE [JAN]; Opera_ID_385; LIDOCAINE [MI]; LIDOCAINE [HSDB]; LIDOCAINE [INCI]; Maybridge1_002571; Prestwick0_000050; Prestwick1_000050; Prestwick2_000050; Prestwick3_000050; Spectrum2_001343; Spectrum3_001392; Spectrum4_000070; Spectrum5_001549; LIDOCAINE [VANDF]; Lopac-L-5647; Lidaform HC (Salt/Mix); Epitope ID:116205; Lidamantle HC (Salt/Mix); 2', 2-(diethylamino)-; LIDOCAINE [USP-RS]; LIDOCAINE [WHO-DD]; LIDOCAINE [WHO-IP]; Neosporin Plus (Salt/Mix); Lopac0_000669; SCHEMBL15689; BSPBio_000179; BSPBio_001359; BSPBio_003004; KBioGR_000079; KBioGR_000599; KBioSS_000079; KBioSS_001598; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; MLS000758263; MLS001074177; MLS001423964; BIDD:GT0342; DivK1c_000174; DivK1c_001323; Lidocaine, analytical standard; SPBio_001525; SPBio_002100; Lidocaine (JP17/USP/INN); LIDOCAINE [GREEN BOOK]; Lidocaine, 1mg/ml in Methanol; BPBio1_000197; GTPL2623; LIDOCAINE [ORANGE BOOK]; SCHEMBL17967359; HMS548M19; KBio1_000174; KBio2_000079; KBio2_001598; KBio2_002647; KBio2_004166; KBio2_005215; KBio2_006734; KBio3_000157; KBio3_000158; KBio3_002224; C01BB01; C05AD01; D04AB01; N01BB02; R02AD02; S01HA07; S02DA01; Lidocaine 1.0 mg/ml in Methanol; LIDOCAINUM [WHO-IP LATIN]; NINDS_000174; Bio1_000379; Bio1_000868; Bio1_001357; Bio2_000079; Bio2_000559; HMS1791D21; HMS1989D21; HMS2051C21; HMS2089E15; HMS2235O14; HMS3371J04; HMS3393C21; HMS3428O07; HMS3651G09; AMY25560; BCP09081; HY-B0185; Tox21_110183; BDBM50017662; NSC789222; s1357; STK552033; AKOS001026768; Tox21_110183_1; CCG-100824; CS-2070; DB00281; NC00074; NSC-789222; SB19118; SDCCGSBI-0050648.P005; WLN: 2N2 & 1VMR B1 F1; .alpha.-Diethylamino-2,6-acetoxylidide; CAS-73-78-9; IDI1_000174; IDI1_033829; NCGC00015611-01; NCGC00015611-02; NCGC00015611-03; NCGC00015611-04; NCGC00015611-05; NCGC00015611-06; NCGC00015611-07; NCGC00015611-08; NCGC00015611-09; NCGC00015611-11; NCGC00015611-12; NCGC00015611-13; NCGC00015611-14; NCGC00015611-15; NCGC00015611-16; NCGC00015611-18; NCGC00015611-31; NCGC00022176-05; NCGC00022176-06; NCGC00022176-07; NCGC00022176-08; NCGC00022176-09; AC-10282; AS-13718; SY052029; 2-(Diethylamino)-2'',6''-acetoxylidide; SBI-0050648.P004; AB00053581; L0156; SW196598-4; A18187; C07073; D00358; M06299; AB00053581-27; AB00053581-28; AB00053581_29; AB00053581_30; EN300-6472705; A833036; Q216935; W-108233; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide #; BRD-K52662033-001-02-6; BRD-K52662033-003-05-5; BRD-K52662033-003-14-7; Z55135799; Lidocaine, British Pharmacopoeia (BP) Reference Standard; Lidocaine, European Pharmacopoeia (EP) Reference Standard; N~1~-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine, United States Pharmacopeia (USP) Reference Standard; 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrate hydrochloride; Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material

    Click to Show/Hide
Structure
Formula
C14H22N2O
IUPAC Name
2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
Canonical SMILES
CCN(CC)CC(=O)NC1=C(C=CC=C1C)C
InChI
InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)
InChIKey
NNJVILVZKWQKPM-UHFFFAOYSA-N
PubChem CID
3676
Full List of Ferroptosis Target Related to This Drug
Cystine/glutamate transporter (SLC7A11)
 Target Info 
In total 2 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Breast cancer ICD-11: 2C60
 Disease Info 
Responsed Regulator hsa-miR-382-5p (miRNA) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Ovarian cancer ICD-11: 2C73
 Disease Info 
Responsed Regulator hsa-miR-382-5p (miRNA) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
Cell proliferation
Cell migration
Cell invasion
In Vitro Model SK-OV-3 cells Ovarian serous cystadenocarcinoma Homo sapiens CVCL_0532
T-47D cells Invasive breast carcinoma Homo sapiens CVCL_0553
In Vivo Model
SPF-level male nude mice aged 56weeks and weighted around 20 g were purchased from Vitalriver (China). All mice were maintained in a 12-hour circadian rhythm, and had free access to water and food. Cancer cells were subcutaneously injected into the right flank of mice. Lidocaine was administrated to mice at a dose of 1.5 mg per kg injected through the vail tails. For control group, the mice were treated with saline. Tumor volume and mice body weight were monitored every 5 days.

    Click to Show/Hide
Response regulation The ovarian and breast cancer cell proliferation was suppressed while cell apoptosis was induced by lidocaine in vitro. Lidocaine attenuated invasion and migration of ovarian and breast cancer cells as well. Regarding the mechanism, lidocaine downregulated solute carrier family 7 member 11 (SLC7A11) expression by enhancing microRNA-382-5p (miR-382-5p) in the cells.
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [2]
Responsed Disease Ischemia/reperfusion injury ICD-11: DB98
 Disease Info 
Responsed Regulator Mitogen-activated protein kinase 14 (MAPK14) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell apoptosis
In Vitro Model A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
Response regulation Lidocaine could regulate inflammation, oxidative stress and ferroptosis by blocking the p38 MAPK signaling pathway. Thus, lidocaine could act as a novel therapeutic treatment of patients with Lung Ischemia-reperfusion (I/R) injury.
References
Ref 1 Lidocaine Promoted Ferroptosis by Targeting miR-382-5p /SLC7A11 Axis in Ovarian and Breast Cancer. Front Pharmacol. 2021 May 26;12:681223. doi: 10.3389/fphar.2021.681223. eCollection 2021.
Ref 2 Lidocaine attenuates hypoxia/reoxygenationinduced inflammation, apoptosis and ferroptosis in lung epithelial cells by regulating the p38 MAPK pathway. Mol Med Rep. 2022 May;25(5):150. doi: 10.3892/mmr.2022.12666. Epub 2022 Mar 4.